Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$245.64
+4.5%
$204.08
$96.09
$246.41
$12.64B0.61698,516 shs917,980 shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$30.47
+2.3%
$28.89
$15.60
$36.44
$3.13B2.252.03 million shs1.57 million shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$20.79
+6.4%
$19.62
$12.58
$23.77
$3.30B1.031.75 million shs1.91 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.48
+3.4%
$22.86
$13.15
$27.72
$12.23B1.695.48 million shs5.13 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.21%+2.12%+8.17%+41.36%+110.12%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+1.29%-4.37%-7.86%+14.19%+60.28%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
+0.10%-4.26%-0.41%-8.82%+32.93%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.26%-0.13%+0.58%-0.01%+69.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$245.64
+4.5%
$204.08
$96.09
$246.41
$12.64B0.61698,516 shs917,980 shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$30.47
+2.3%
$28.89
$15.60
$36.44
$3.13B2.252.03 million shs1.57 million shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$20.79
+6.4%
$19.62
$12.58
$23.77
$3.30B1.031.75 million shs1.91 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.48
+3.4%
$22.86
$13.15
$27.72
$12.23B1.695.48 million shs5.13 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.21%+2.12%+8.17%+41.36%+110.12%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+1.29%-4.37%-7.86%+14.19%+60.28%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
+0.10%-4.26%-0.41%-8.82%+32.93%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.26%-0.13%+0.58%-0.01%+69.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.90
Moderate Buy$251.262.29% Upside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.71
Moderate Buy$46.8353.70% Upside
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
2.87
Moderate Buy$34.2564.74% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2015.18% Upside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, AXSM, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy
5/22/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOverweight$40.00 ➝ $35.00
5/22/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Set Price Target$31.00
5/21/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Reiterated RatingBuy$80.00
5/14/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOverweight$42.00 ➝ $40.00
5/13/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Set Price Target$39.00
5/13/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Lower Price TargetOutperform$40.00 ➝ $39.00
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/11/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Reiterated RatingBuy$39.00
5/8/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOutperform$25.00 ➝ $23.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M19.80N/AN/A$1.75 per share140.37
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$139.74M22.43N/AN/A$12.20 per share2.50
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M9.98N/AN/A$6.91 per share3.01
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.59$2.41 per share10.18$13.18 per share1.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A50.65N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A20.071.55-4.95%7.42%3.66%8/6/2026 (Estimated)

Latest DNLI, BEAM, AXSM, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million
5/7/2026Q1 2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.09
16.99
16.99
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
0.01
9.28
9.28
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.80%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12.50%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510102.88 million98.97 millionOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430158.71 million138.87 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$245.64 +10.50 (+4.47%)
Closing price 04:00 PM Eastern
Extended Trading
$245.71 +0.07 (+0.03%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$30.47 +0.69 (+2.32%)
Closing price 04:00 PM Eastern
Extended Trading
$29.90 -0.57 (-1.87%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$20.79 +1.25 (+6.40%)
Closing price 04:00 PM Eastern
Extended Trading
$20.77 -0.02 (-0.10%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.48 +0.80 (+3.39%)
Closing price 03:59 PM Eastern
Extended Trading
$24.73 +0.25 (+1.01%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.